http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011150283-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 2010-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011150283-A |
| titleOfInvention | TTK PEPTIDES AND VACCINES THEREOF |
| abstract | 1. The selected peptide containing the amino acid sequence of SEQ ID NO: 3.2. An isolated peptide capable of inducing cytotoxic T lymphocytes (CTL), the peptide containing the amino acid sequence of SEQ ID NO: 3, in which 1, 2 or more amino acids are substituted, deleted or added. 3. The selected peptide according to claim 2, which has one or both of the following characteristics: (a) the second amino acid at the N-terminus is or is modified to be an amino acid selected from the group consisting of leucine and methionine, and (b ) The C-terminal amino acid is or is modified to be an amino acid selected from the group consisting of valine and leucine. 4. The selected peptide according to any one of claims 1 to 3, which is a nonapeptide. An isolated polynucleotide encoding a peptide according to any one of claims 1 to 4. A CTL inducing agent, wherein the agent contains one or more peptides according to any one of claims 1 to 4, or one or more polynucleotides according to claim 57. A pharmaceutical agent for treating and / or preventing cancer and / or preventing its postoperative recurrence, wherein the agent contains one or more peptides according to any one of claims 1 to 4 or one or more polynucleotides according to claim 5.8. The pharmaceutical agent according to claim 7, prepared for administration to an individual in whom the HLA-A antigen is HLA-A2.9. The pharmaceutical agent of claim 8, wherein the HLA-A2 antigen is HLA-A * 0201.10. The pharmaceutical agent of claim 7 or 8, wherein the agent is prepared for the treatment of cancer. A method of inducing an antigen presenting cell (APC) having the ability to induce |
| priorityDate | 2009-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.